Durm GA, Jabbour SK, Althouse SK, et al. - In patients with unresectable stage III non–small cell lung cancer (NSCLC), researchers assessed pembrolizumab as consolidation therapy following concurrent chemoradiation. Concurrent chemoradiation using cisplatin and etoposide, cisplatin and pemetrexed, or carboplatin and paclitaxel and 59.4 to 66.6 Gy of radiation was received by patients with unresectable stage III NSCLC. They enrolled patients with nonprogression of disease, and these patients were administered pembrolizumab (200 mg intravenously every 3 weeks for up to 12 months). The median time to metastatic disease or death (TMDD) was estimated to be 30.7 months. The median progression‐free survival (PFS) and overall survival (OS) were 18.7 months and 35.8 months, respectively. Overall, findings revealed that improved TMDD, PFS, and OS were afforded by consolidation pembrolizumab following concurrent chemoradiation vs historical controls of chemoradiation alone. Similar rates of grade 3 to 5 pneumonitis vs chemoradiation alone were documented.